Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Ko

Showing results (21-30 of 99) with videos related to

Pageof 10
Sort By:
Anticancer Research|July 5, 2020
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the LiteratureShohei T Burns, Lloyd Damon, Naomi Akagi, et al.
International Journal of Cancer|August 6, 2014
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control studyEvan J Walker, Andrew H Ko, Elizabeth A Holly, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancerEvan J Walker, Jeffry P Simko, Eric K Nakakura, et al.
Cancer|February 5, 2015
Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control studyEvan J Walker, Andrew H Ko, Elizabeth A Holly, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and valueDaniel H Ahn, Andrew H Ko, Neal J Meropol, et al.
American Journal of Clinical Oncology|October 22, 2019
CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic AdenocarcinomaCelso L Diaz, Pelin Cinar, Jimmy Hwang, et al.
Immunotherapy|August 2, 2021
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancerErica S Tsang, Evan J Walker, Julia Carnevale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreasAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Investigation|January 9, 2008
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II studyAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Pancreas|September 26, 2008
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapyDerrick Wong, Andrew H Ko, Jimmy Hwang, et al.
Pageof 10

Showing results (21-30 of 99) with videos related to

Sort By:
Pageof 10
Anticancer Research|July 5, 2020
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the LiteratureShohei T Burns, Lloyd Damon, Naomi Akagi, et al.
International Journal of Cancer|August 6, 2014
Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control studyEvan J Walker, Andrew H Ko, Elizabeth A Holly, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancerEvan J Walker, Jeffry P Simko, Eric K Nakakura, et al.
Cancer|February 5, 2015
Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control studyEvan J Walker, Andrew H Ko, Elizabeth A Holly, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and valueDaniel H Ahn, Andrew H Ko, Neal J Meropol, et al.
American Journal of Clinical Oncology|October 22, 2019
CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic AdenocarcinomaCelso L Diaz, Pelin Cinar, Jimmy Hwang, et al.
Immunotherapy|August 2, 2021
Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancerErica S Tsang, Evan J Walker, Julia Carnevale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2005
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreasAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Investigation|January 9, 2008
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II studyAndrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Pancreas|September 26, 2008
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapyDerrick Wong, Andrew H Ko, Jimmy Hwang, et al.
Pageof 10